AEZS-112 follow-up compounds (AEterna Zentaris)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug NameAEZS-112 follow-up compounds (AEterna Zentaris)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin modulatorsTopoisomerase II inhibitors
TargetsTubulinTopoisomerase II
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCOSCIENS Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCOSCIENS Biopharma Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A